{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T18:59:21Z","timestamp":1769626761604,"version":"3.49.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:p>Uterine carcinosarcoma (UCS) is an aggressive malignancy with few treatment options. A recent clinical trial has shown an increase in progression-free survival in patients with human epidermal growth factor receptor 2 (HER2)-positive serous endometrial carcinomas treated with anti\u2013HER2-targeted therapies. Few studies have evaluated HER2 expression\/amplification in UCS. Similar to serous endometrial carcinoma, the majority of UCS have <jats:italic toggle=\"yes\">TP53<\/jats:italic> mutations and a serous epithelial component, suggesting that UCS may show similar rates of HER2 positivity and therapeutic response. Therefore, we evaluated HER2 expression\/amplification in a cohort of UCS over a 5-year period. HER2 immunohistochemistry (IHC) and chromogenic in situ hybridization were performed on tissue microarray and whole tissue sections and scored according to the most recent clinical trial recommendations. Three of 48 UCS (6%) had strong (3+) HER2 IHC expression, and 3 cases (6%) were equivocal (2+). Seven cases (15%) had HER2 amplification by chromogenic in situ hybridization, including all 3 with overexpression and 2 that were equivocal by IHC. Mismatch repair (MMR) protein, p53, and programmed cell death-ligand 1 (PD-L1) expression status was obtained from prior whole section analyses. All HER2-positive cases had a serous morphology and aberrant p53 expression. Only minimal PD-L1 expression was seen in the HER2-positive cases, and none had MMR loss. A subset of UCS with serous morphology have overexpression and\/or amplification of HER2, which may predict response to HER2-targeted therapies. HER2-positive UCS may be less susceptible to immune checkpoint inhibition as they uncommonly show MMR deficiency and\/or strong PD-L1 expression. Thus, HER2-targeted therapies could be of clinical utility in a subset of UCS without other adjuvant treatment options.<\/jats:p>","DOI":"10.1097\/pas.0000000000001870","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T04:00:35Z","timestamp":1644206435000},"page":"435-442","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":29,"title":["HER2 Overexpression and Amplification in Uterine Carcinosarcomas With Serous Morphology"],"prefix":"10.1097","volume":"46","author":[{"given":"Taylor M.","family":"Jenkins","sequence":"first","affiliation":[{"name":"Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leigh A.","family":"Cantrell","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology, University of Virginia, Charlottesville, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark H.","family":"Stoler","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne M.","family":"Mills","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"R1-20250612","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ygyno.2015.03.041","article-title":"Uterine carcinosarcoma: a review of the literature","volume":"137","author":"Cantrell","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R2-20250612","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/gcc.22113","article-title":"Marked heterogeneity of HER2\/NEU gene amplification in endometrial serous carcinoma","volume":"52","author":"Buza","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"R3-20250612","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5858\/arpa.2012-0416-RA","article-title":"HER2\/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges","volume":"138","author":"Buza","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"R4-20250612","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41379-019-0358-x","article-title":"HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy","volume":"33","author":"Rottmann","year":"2020","journal-title":"Mod Pathol"},{"key":"R5-20250612","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5858\/arpa.2020-0207-RA","article-title":"HER2 testing in endometrial serous carcinoma: time for standardized pathology practice to meet the clinical demand","volume":"145","author":"Buza","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"R6-20250612","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2020.07.016","article-title":"Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: a multi-institutional cohort study","volume":"159","author":"Erickson","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R7-20250612","doi-asserted-by":"crossref","first-page":"100554","DOI":"10.1016\/j.gore.2020.100554","article-title":"Selection of HER2\/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma","volume":"32","author":"Pelligra","year":"2020","journal-title":"Gynecol Oncol Rep"},{"key":"R8-20250612","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"key":"R9-20250612","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R10-20250612","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccell.2017.02.010","article-title":"Integrated molecular characterization of uterine carcinosarcoma","volume":"31","author":"Cherniack","year":"2017","journal-title":"Cancer Cell"},{"key":"R11-20250612","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1097\/PAS.0000000000001434","article-title":"Mismatch repair deficiency in uterine carcinosarcoma: a multi-institution retrospective review","volume":"44","author":"Jenkins","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R12-20250612","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/PGP.0000000000000752","article-title":"PD-L1 and mismatch repair status in uterine carcinosarcomas","volume":"40","author":"Jenkins","year":"2021","journal-title":"Int J Gynecol Pathol"},{"key":"R13-20250612","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Getz","year":"2013","journal-title":"Nature"},{"key":"R14-20250612","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/his.14381","article-title":"Performance of a HER2 testing algorithm specific for p53-abnormal endometrial cancer","volume":"79","author":"Vermij","year":"2021","journal-title":"Histopathology"},{"key":"R16-20250612","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00428-021-03017-5","article-title":"Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy","volume":"478","author":"Yoshida","year":"2021","journal-title":"Virchows Arch"},{"key":"R17-20250612","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/ijgc-2019-000920","article-title":"Molecular variations in uterine carcinosarcomas identify therapeutic opportunities","volume":"30","author":"Crane","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"R18-20250612","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ygyno.2005.07.124","article-title":"EGFR expression and HER2\/neu overexpression\/amplification in endometrial carcinosarcoma","volume":"100","author":"Livasy","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R19-20250612","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ygyno.2006.11.001","article-title":"Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets","volume":"105","author":"Cimbaluk","year":"2007","journal-title":"Gynecol Oncol"},{"key":"R20-20250612","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/ijc.30537","article-title":"Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas","volume":"140","author":"Jones","year":"2017","journal-title":"Int J Cancer"},{"key":"R21-20250612","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/PAS.0000000000000182","article-title":"HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas","volume":"38","author":"Mentrikoski","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R22-20250612","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/PAI.0000000000000457","article-title":"PD-L1 expression in carcinosarcomas of the gynecologic tract: a potentially actionable biomarker","volume":"26","author":"Pinto","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R23-20250612","doi-asserted-by":"crossref","first-page":"152847","DOI":"10.1016\/j.prp.2020.152847","article-title":"Landscape of immune checkpoint inhibition in carcinosarcoma (MMMT): analysis of IDO-1, PD-L1 and PD-1","volume":"216","author":"Hacking","year":"2020","journal-title":"Pathol Res Pract"},{"key":"R24-20250612","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/PGP.0000000000000690","article-title":"Does specimen type have an impact on HER2 status in endometrial serous carcinoma? Discordant HER2 status of paired endometrial biopsy and hysterectomy specimens in the presence of frequent intratumoral heterogeneity","volume":"40","author":"Rottmann","year":"2021","journal-title":"Int J Gynecol Pathol"},{"key":"R25-20250612","doi-asserted-by":"crossref","first-page":"100561","DOI":"10.1016\/j.gore.2020.100561","article-title":"Human epidermal growth factor receptor 2 (Her2) testing for uterine serous carcinoma: report of scenarios of unusual overexpression","volume":"32","author":"Quddus","year":"2020","journal-title":"Gynecol Oncol Rep"},{"key":"R26-20250612","first-page":"114","article-title":"Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity","volume":"60","author":"Fujii","year":"2000","journal-title":"Cancer Res"},{"key":"R27-20250612","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod Pathol"},{"key":"R28-20250612","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41379-021-00746-5","article-title":"Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study","volume":"34","author":"Buza","year":"2021","journal-title":"Mod Pathol"},{"key":"R29-20250612","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular Classification of the PORTEC-3 Trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T17:00:53Z","timestamp":1749747653000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001870","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,3]]}}}